Get alerts:The combined company would retain the Supernus name, be headquartered in Rockville, Maryland, and be led by Supernus President and Chief Executive Officer Jack Khattar. Under the agreement, Supernus shareholders would receive 1.5401 shares of Indivior common stock for each Supernus share they own. The post-merger board would include four directors from each company, including Khattar from Supernus and Kingsley from Indivior. Supernus Chief Financial Officer Tim Dec said the combined company is expected to have roughly 215 million shares outstanding after the deal closes. About Supernus Pharmaceuticals (NASDAQ:SUPN)Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies.